Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABFRA:61MA -0.22%91 Operating Margin % is 14.93% as of Mar. 2026, which is 34% above its 10-year median of 11.11. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.10 (Fairly Valued). Among 816 Medical Devices & Instruments companies, MedCap AB ranks better than 77.7% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. MedCap AB's Operating Income for the
three
months ended in Mar. 2026 was €7.7 Mil. MedCap AB's Revenue for the
three
months ended in Mar. 2026 was €51.7 Mil. Therefore, MedCap AB's Operating Margin % for the quarter that ended in Mar. 2026 was 14.93%.
Good Sign:
MedCap AB operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for MedCap AB's Operating Margin % or its related term are showing as below:
FRA:61MA'
s Operating Margin % Range Over the Past 10 Years
Min: 0.2 Med: 11.11 Max: 14.72
Current: 14.72
FRA:61MA's Operating Margin % is ranked better than 77.7% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.28
vs FRA:61MA: 14.72
MedCap AB's 5-Year Average Operating Margin % Growth Rate was 6.00% per year.
MedCap AB's Operating Income for the
three
months ended in Mar. 2026 was €7.7 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €29.3 Mil.
MedCap AB (FRA:61MA) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
MedCap AB Operating Margin % Related Terms
MedCap AB Operating Margin % Historical Data
* Premium members only.
The historical data trend for MedCap AB's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:61MA vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, MedCap AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where MedCap AB's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
MedCap AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (FRA:61MA) has a Operating Margin % of 14.93% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on MedCap AB and its competitors. This is 34% above median its historical median of 11.11. Over the past decade, MedCap AB's Operating Margin % has ranged from 0.20 to 14.72. According to the industry distribution chart, MedCap AB ranks #182 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.3%.
Is MedCap AB's Operating Margin % too high?
MedCap AB's current Operating Margin % of 14.93% is 34% above median its 10-year median of 11.11. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 14.72. The Medical Devices & Instruments industry median Operating Margin % is 3.28. MedCap AB's value of 14.93% is 355.2% above this industry median. Based on the distribution chart, MedCap AB ranks #182 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #182 out of 816 companies for Operating Margin %. This places MedCap AB in the top 22% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.28. MedCap AB's value of 14.93% is 355.2% above this benchmark. Historically, MedCap AB's own Operating Margin % has ranged from 0.20 to 14.72 over the past decade. While the company's 10-year median is 11.11 vs. the industry median of 3.28, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.28, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current Operating Margin % of 14.93% is 355.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Operating Margin % is 14.93%, which is 34% above median its own 10-year median of 11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.10, compared to a current price of €45.54 — trading 9.1% below its estimated fair value. The current Operating Margin % is 14.93%, which is 34% above median its 10-year median of 11.11 and 355.2% above the Medical Devices & Instruments industry median of 3.28. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current Operating Margin % is 14.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (FRA:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €45.54 is trading 9.1% below its estimated GF Value™ of €50.10.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for FRA:61MA:
Operating Margin %: 14.93% (34% above median its 10-year median of 11.11)
GF Value™: €50.10 vs. price of €45.54 (9.1% below fair value)
Industry Position: 355.2% above the Medical Devices & Instruments median (#182 of 816)
No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score
Get the complete analysis for FRA:61MA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61MA has been successfully added to your 
